Vaccines Improve Public Opinion Of Pharma, Despite Cost Worries With Chart: Public Holds Favorable Views of Big Pharma, But Still Wants Drug Pricing Reforms

In recent years, the pharmaceutical industry has not been popular with the public: Problems like the rising cost of prescription drugs and the opioid epidemic combined to make the industry the least popular nationwide in a 2019 Gallup poll. According to a recent poll, the public now thinks better of the industry due to the rapid development of COVID-19 vaccines — but still wants drug prices to be reined in.

In a March 2021 national survey, progressive polling group Data for Progress found that 56% of respondents had a favorable view of pharmaceutical companies (see infographic, p. 6). Vaccine developers scored well on an individual basis: majorities had favorable views of Johnson & Johnson (68%), Moderna, Inc. (60%) and Pfizer Inc. (65%). Also, 75% of respondents said they approve of those specific companies’ vaccine development efforts. However, the poll also found that 73% of respondents disapprove of “how pharmaceutical companies are handling the rising cost of prescription drugs.”

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

bills-and-pills
January 26

Medicare Enrollees May Still Face Affordability Issues After Part D Benefit Redesign

READ MORE
pills-in-hand
January 26

ICER Report Aims to Nudge Payers Toward Fairer Drug Coverage Policies

READ MORE
businessman-viewing-news-update-journalism-headline-on-a-laptop
January 26

News Briefs: Lilly Alzheimer’s Drug Fails to Win Accelerated Approval

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today